c3n project webcast with ginger.io - august 21, 2012
TRANSCRIPT
![Page 1: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/1.jpg)
LIVE WEBCAST | FeaturingAugust 21, 2012
C3N Supported by NIH NIDDK R01DK085719
AHRQ R01HS020024 AHRQ U18HS016957
![Page 2: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/2.jpg)
Welcome!• We will pause for questions after
the C3N Project overview, and at
the conclusion of our feature
presentation we will host more
time for Q&A; but you can also
direct questions and comments
anytime using the chat function
• After the presentation, a short
survey will appear – thanks for your
feedback + participation!
• First, a few technology pointers…
Peter Margolis, MD, PhD
Michael Seid, PhD
![Page 4: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/4.jpg)
Raising Your Hand
4
Raise your hand Lower your hand
![Page 5: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/5.jpg)
Writing Comments & Asking Questions
CLICK HERE TO OPEN BOX.
TYPE YOUR QUESTION HERE!
![Page 6: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/6.jpg)
6
take the conversation to twitter
#C3N@C3NProject@Ginger_io
![Page 7: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/7.jpg)
An Introduction of the C3N Projectwith Dr. Peter Margolis
![Page 8: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/8.jpg)
What if….?
• …we could create a vastly better chronic care system
by harnessing inherent motivation and collective
intelligence of patients and clinicians?
• … this system allowed patients and physicians to
share information, collaborate to solve problems, use
their collective creativity and expertise to act in ways
that improve health?
![Page 10: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/10.jpg)
What is the C3N?
• Self-reinforcing network
• “Lab” and “proving ground”
• A social, technical and scientific platform to support a learning health system
![Page 11: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/11.jpg)
Learning Health Systems
• Patients and providers work together to choose care
based on best evidence
• Drive discovery as natural outgrowth of patient care
• Ensure innovation, quality, safety and value
• All in real-time
Institute of Medicine
![Page 12: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/12.jpg)
Design
Observation
Synthesis
Screen
Test Adapt, Implement & Spread
Prototype testing
Pilottesting
Concept design
Generate new ideas Test new ideas Spread new ideas
C3N Design Process
![Page 13: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/13.jpg)
Creating Conditions for a C3N
1. Align motivation around common vision
2. Make it easy to contribute
– design, system engineering and technology
3. Enable better communication
4. Reduce “transactional” costs
![Page 14: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/14.jpg)
![Page 15: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/15.jpg)
Percent of Patients in Remission
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Jul-2007 N
=338
Aug-2
007 N
=396
Sep-2
007 N
=428
Oct-
20
07 N
=4
79
Nov-2
007 N
=508
Dec-2
007 N
=531
Jan-2
008 N
=570
Fe
b-2
008 N
=607
Mar-
2008 N
=643
Ap
r-2
00
8 N
=6
54
May-2
008 N
=667
Jun-2
008 N
=671
Jul-2008 N
=686
Aug-2
008 N
=731
Sep-2
008 N
=754
Oct-
20
08 N
=8
01
Nov-2
008 N
=832
Dec-2
008 N
=901
Jan-2
009 N
=973
Fe
b-2
009 N
=995
Mar-
2009 N
=1021
Apr-
2009 N
=1070
May-2
009 N
=1112
Jun-2
009 N
=1194
Jul-2009 N
=1240
Aug-2
009 N
=1277
Sep-2
009 N
=1314
Oct-
2009 N
=1344
Nov-2
009 N
=1366
Dec-2
009 N
=1400
Jan-2
010 N
=1421
Fe
b-2
010 N
=1410
Mar-
2010 N
=1440
Apr-
2010 N
=1455
May-2
010 N
=1461
Jun-2
010 N
=1471
Jul-2010 N
=1489
Aug-2
010 N
=1518
Sep-2
010 N
=1547
Oct-
2010 N
=1576
Nov-2
010 N
=1985
Dec-2
010 N
=2032
Jan-2
011 N
=2043
Fe
b-2
011 N
=2065
Mar-
2011 N
=2124
Apr-
2011 N
=2191
May-2
011 N
=2206
Jun-2
011 N
=2272
Jul-2011 N
=2301
Aug-2
011 N
=2335
Pe
rce
nt
of
Pat
ien
ts
Month
Percent of IBD Patients in Remission (PGA)
![Page 16: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/16.jpg)
Why Crohn’s as a Prototype?
• Number of patients small
• Few incentives for industry to invest in research
• No center has enough patients
• Teenagers especially likely to use Internet
communications
![Page 17: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/17.jpg)
![Page 18: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/18.jpg)
Reducing Transactional Costs Example: Data Collection
![Page 20: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/20.jpg)
“Enhanced” Registry
• Research using distributed registry of 10,000 patients
• Automated Pre-visit Prompts
• Automated Physician Pre-Visit Planning
![Page 21: C3N Project Webcast with Ginger.io - August 21, 2012](https://reader030.vdocument.in/reader030/viewer/2022032616/55a8ea371a28abcb0e8b45bd/html5/thumbnails/21.jpg)
Infliximab and Thiopurine Treatment by Site
0%
10%
20%
30%
40%
50%
60%
70%
Sites
Perc
en
tag
e o
f C
D P
ati
en
ts
Infliximab Thiopurine
“Enhanced” Registry - Research